TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04775004

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bone marrow venting procedure (BMVP)
Description: The BMVP involves creating small holes in a non-weight bearing area of the bone that does not have any important structures; the holes act as channels, which allow for flow of the participants own biologic products and stem cells from within the bone marrow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma (PRP)
Description: The PRP group will have 40cc to 60cc (about 3 tablespoons) of blood drawn at the time of surgery. The blood sample will then be prepared in a centrifuge machine to collect a component of the blood called platelet rich plasma. Once appropriate concentrations of the PRP are confirmed, the PRP will be injected into the subject's knee prior to wound closure.
Study: NCT04242823

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Automated visual evaluation
Description: Participants will undergo primary hrHPV testing and if positive will be referred for VIA per Botswana and WHO guidelines. Participants will also undergo colposcopy, image capture for automated visual evaluation and biopsy at the time of VIA.
Study: NCT06395792

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.
Study: NCT06508905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep buddy
Description: The toy chosen as a sleep companion was introduced to the children in the experimental group and they were told that it would accompany them for 3 days during their hospitalization. Before giving the sleep companion, parents and children were informed about the sleep companion and their questions about the study were answered. Children who did not have their own sleep companion were included in the sample. The child was encouraged to sleep and spend time with the given sleep buddy and the family was also informed.
Study: NCT05554198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attend Behavior Parent Training
Description: Attend Behavior is a Parent Training intervention available in application form for smartphones or online. Attend Behavior consists of 12 instructional modules and it is recommended that parents complete one module a week in addition to practicing the techniques taught in that course. Each learning module typically around 30 minutes to complete and includes an introductory video to give parents an overview of the different features of the application. At the start of the intervention, parents will take an assessment that will provide information for the program to create individualized goals, plans, reinforcement agents, and even daily schedules. A HIPPA compliant clinician portal within the application allows the clinician to have real time access to monitor the parent learning progress, tracked behaviors, parental notes, and message with the parent.
Study: NCT06123689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMT-Regenera activa
Description: Patient's preparation: is an ambulatory procedure, the sterility of the Micrograft and the method should be guaranteed during the whole procedure.~Punch biopsy extraction:~The punch should be obtained by the posterior auricular shell area. The zone cleaned with antiseptic solution. Anesthesia is applied in the posterior zone in the base area of the auricular shell. It should be applied superficially to separate the skin from the cartilage . Should be obtained by 3 dermic punches of 2,5mm diameter. The skin is separated from the perichondrium and cartilage.~1. Once the samples are obtained, they must be put on the metallic grid of the Rigeneracon~2. Afterwards, 4 ml of Saline solution are added in the inferior part of the Rigeneracon, then close the lid and then put it in the machine with the needed adaptors.~3. The samples are processed for 6 minutes~4. The Rigeneracon is extracted from the machine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalubrix
Description: Patients randomized in Group 2 Sodim Hyaluronate (Hyalubrix 60 -1,5%-2ml vial). NOTE: For the infiltration in the medial knee compartment treatment, the use of intramuscular needle is recommended.~The care post-treatment The homeostasis of the donor's area is achieved by mechanical compression. Usually, there is no need of stitches.~Often it can be seen a bit of inflammation during the first 24-72 hours. The use of analgesic drugs is recommended, avoiding the NSAID, they can interfere in the function of micrografts. Apply intermittently cold on the area or a compressive bandage, if needed
Study: NCT05364424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Participants will receive intravenous (IV) glofitamab for up to 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants will receive IV obinutuzumab on Cycle 1 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as necessary to manage cytokine release syndrome (CRS) events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive up to 2 doses of IV rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Participants will receive IV ifosfamide for up to 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV carboplatin for up to 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Participants will receive IV etoposide for up to 3 cycles.
Study: NCT05757453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Mobile platform
Study: NCT06581939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation group
Description: In the rehabilitation group, patients will follow an individualized rehabilitation program started early in the ICU and continued in the post-ICU ward then at home for 12 weeks, combining goal-directed nutrition and physical activity, tailored to gains made over time by each patient, with the involvement of dieticians, physiotherapists, and adapted-physical-activity instructors.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: In the control group, patients will receive usual care from day-0 to day-180.
Study: NCT05127785

Intervention type: PROCEDURE
Intervention: LVAD or Heart Transplant
Description: Patients undergoing advanced heart failure intervention including LVAD implantation or heart transplantation
Study: NCT05283707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paula Method Exercises
Description: The Paula Method Exercises were administered by the researcher for 6 to 8 hours, for 10 to 15 minutes on the post-op first day and post-op second day, to women who had a cesarean section.
Study: NCT06148610

Intervention type: DEVICE
Intervention: NewSpringForMe digital solution
Description: Follow-up of transplanted patients for hematological diseases using the NewSpringForMe device as support of quality of life
Study: NCT06375876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-session intervention (SSI)
Description: The SSI focuses on increasing hope among women who experience IPV using facts about the brain and IPV research, stories from survivors, and writing exercises.
Study: NCT05414942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid Reduction Program
Description: Subjects will engage in a brief, educational session which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
Study: NCT04621929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine / Topiramate Oral Product
Description: All participants in the experimental group will receive oral generic tablet phentermine (18.75 or 37.5 mg dose) and topiramate (daily 100 mg or 150 mg dose)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Citrate Salts, Allopurinol, Diet
Description: Control participants will complete initial visit requirements and study enrollment and will be maintained on their current therapy.
Study: NCT06105892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Eye Rotation Vision Exercise (VERVE)
Description: VERVE utilizes a virtual reality (VR) headset with integrated eye-tracking where the patient makes specific vergence eye movements by playing a VR game controlled by eye movements. Participants will be making convergence and divergence eye movements as steps and ramps.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Eye Rotation Vision Exercise (VERVE)
Description: VERVE utilizes a virtual reality (VR) headset with integrated eye-tracking where the patient makes specific vergence eye movements by playing a VR game controlled by eye movements. Participants will be making convergence and divergence eye movements as steps and ramps.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR Therapy
Description: VERVE game without changes in eye movement demands. Maximizing gameplay with no intervention.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VR Therapy
Description: VERVE game without changes in eye movement demands. Maximizing gameplay with no intervention.
Study: NCT06604598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBU-PCT-DEX
Description: Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IBU-PCT-placebo
Description: Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, and 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the IBU-PCT-placebo intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCT-placebo-placebo
Description: Paracetamol (Bernofarm) 2x1 gr iv, 2xplacebo (normal saline alike paracetamol), 2xplacebo (normal saline alike dexamethasone) will be given with interval 8 hour, within the PCT-placebo-placebo intervention.
Study: NCT05655988

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: inguinal ultrasonography
Description: After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: inguinal ultrasonography
Description: After a total extraperitoneal inguinal hernia operation performed using a fixation-free mesh, ultrasonography will be performed on all patients to calculate the slip size of the mesh.
Study: NCT04774146

Intervention type: PROCEDURE
Intervention: pars plana vitrectomy
Description: silicone oil active aspiration and isovolumetric BSS replacement followed by irrigation and /o gas fluid exchange

Intervention type: PROCEDURE
Intervention: pars plana vitrectomy
Description: silicone oil active aspiration and isovolumetric BSS replacement followed by irrigation and /o gas fluid exchange
Study: NCT06688669

Intervention type: OTHER
Intervention: Fabrication of suitable complete or removable partial dentures for the patient
Description: Fabrication of suitable complete and partial dentures for the patient. The study will not interfere with this treatment process; only follow-up assessments will be conducted at specific intervals after the dentures are fabricated, and surveys will be administered to the patient.

Intervention type: OTHER
Intervention: Fabrication of suitable complete or removable partial dentures for the patient
Description: Fabrication of suitable complete and partial dentures for the patient. The study will not interfere with this treatment process; only follow-up assessments will be conducted at specific intervals after the dentures are fabricated, and surveys will be administered to the patient.
Study: NCT06691373

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: Static stretching of the quadriceps and hamstrings which was performed in the dominant limb, and held in a position where the participants referred discomfort:~* Quadriceps - participants were in the standing position, with one hand holding the back of a chair to maintain the balance, and were instructed to pull the ankle of the lower limb to be stretched, pressing the heel towards the buttocks and, at the same time, extending the thigh;~* Hamstrings - participants were also in the standing position, with the heel resting on a chair. They were then instructed to lean the body forward keeping the spine erect and the pelvis in anteversion, to obtain a stretch over the knee and hip.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching
Description: Static stretching of the quadriceps and hamstrings which was performed in the dominant limb, and held in a position where the participants referred discomfort:~* Quadriceps - participants were in the standing position, with one hand holding the back of a chair to maintain the balance, and were instructed to pull the ankle of the lower limb to be stretched, pressing the heel towards the buttocks and, at the same time, extending the thigh;~* Hamstrings - participants were also in the standing position, with the heel resting on a chair. They were then instructed to lean the body forward keeping the spine erect and the pelvis in anteversion, to obtain a stretch over the knee and hip.
Study: NCT06689644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nootropics (ginkgo biloba, nicergoline, piracetam, or others)
Description: Commercially available product: Mind lab pro

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A cellulose commonly used as a bulking agent in supplement products

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Perceptual decision-making performance
Description: A computerised cognitive task involving rapid visual categorisation of images

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual decision-making performance
Description: A computerised cognitive task involving rapid visual categorisation of images

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electroencephalography
Description: Brain signals are recorded from a 64 channel EEG system during the cognitive task

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Brain signals are recorded from a 64 channel EEG system during the cognitive task
Study: NCT05268237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Sublingual or subcutaneous liraglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Sublingual or subcutaneous liraglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sublingual placebo
Study: NCT06491667

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
Study: NCT06217159

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Poikilocapnia
Description: Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will wear a specialized face mask and breathe room air for 60 min. The face mask will be attached to an automated gas-blender system; however, only room air will be delivered.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normocapnia
Description: Following ingestion of 0.6 g β-OHB/kg body weight ketone monoester, participants will be outfitted with a specialized face mask and breathe air with a slightly higher concentration of CO2 to maintain PetCO2 to resting baseline values for 60 min. Gas will be continuously delivered by an automated gas-blender system.
Study: NCT06138080

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography
Description: We have no specific intervention. We investigate different diagnostic modalities of VUR.
Study: NCT06545955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadofaragene Firadenovec
Description: vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadofaragene Firadenovec
Description: vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadofaragene Firadenovec
Description: vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.
Study: NCT06491667

Intervention type: DIAGNOSTIC_TEST
Intervention: C-reactive protein
Description: Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction

Intervention type: DIAGNOSTIC_TEST
Intervention: C-reactive protein
Description: Explore the role of Neutrophil-lymphocyte ratio C-reactive protein in predicting the imediate and short-term prognosis in ST-segment elevation myocardial infarction
Study: NCT05762770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PICSI
Description: Using HA-binding as a sperm selection tool, the intervention group will have sperm selected physiologically prior to ICSI using PICSI dishes, following ORIGIO recommended methods (CooperSurgical, 2021).
Study: NCT05397405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
Study: NCT06104306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Tablets administered without regard to food
Study: NCT06260618

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam
Description: GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine skin, Gelatin USP Granules and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitodex
Description: The Chitogel Endoscopic Sinus Surgery Kit contains components and equipment for the preparation of a nasal gel to be applied to the sinus cavities via a supplied and specifically designed malleable cannula.~The Gel preparation will take approximately 30 minutes, so preparation must start sufficiently in advance of when the Gel is expected to be used in surgery.~Once the Gel has been prepared it should be applied to the sinus cavities on both sides within six hours using the malleable cannula supplied with the Kit.~The Gel must be prepared on a sterile surface following these instructions. There are two main components to the Gel.~1. Dextran Aldehyde (B), which is a dry powder, and is reconstituted into a liquid form through mixing the powder with a liquid Sodium Phosphate Buffer (A). Both of these components are supplied sterile.~2. The second component Chitosan Succinamide (C), is a liquid and is also supplied sterile.
Study: NCT04851015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: 10mg/kg/day of TMP component

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim-sulfamethoxazole
Description: 15mg/kg/day of TMP component
Study: NCT05460000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 cycles chemotherapy instead of 6 cycles chemotherapy
Description: We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 cycles chemotherapy
Description: Standard chemotherapy as comparator
Study: NCT05465876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVUSHELD
Description: EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab. The single dose, is to be administered intramuscular, each mAb sequentially into the deltoid
Study: NCT05067244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: MDMA assisted psychotherapy
Study: NCT05994534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cysteamine Bitartrate
Description: Single dose, tablets at current therapeutic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine Amide
Description: Single dose, oral solution
Study: NCT05705128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be given with bupivaciane for postoperative pain control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be given with bupivaciane for postoperative pain control
Study: NCT06104618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given IV
Study: NCT05464836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-103
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO